RS7 antibodies
AssigneeImmunomedics, Inc.
InventorsSerengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunomedics, Inc.
InventorsSerengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
Estimating the term…
This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
An isolated nucleic acid encoding a chimeric, humanized or human anti-TROP-2 antibody, wherein the anti-TROP-2 antibody comprises the light chain complementarity determining region (CDR) sequences CDR1 (KASQDVSIAVA, SEQ ID NO:28), CDR2 (SASYRYT, SEQ ID NO:29), and CDR3 (QQHYITPLT, SEQ ID NO:30) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:31), CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:32), and CDR3 (GGFGSSYWYFDV, SEQ ID NO:33).
Dependencies are inferred from the claim text.